Publications
  1. Audrey M. Hendley, Arjun A. Rao, Laura Leonhardt, Sudipta Ashe, Jennifer A. Smith, Simone Giacometti, Xianlu L Peng, Honglin Jiang, David I. Berrios, Mathias Pawlak, Lucia Y. Li, Jonghyun Lee, Eric A. Collisson, Mark Anderson, Gabriela K. Fragiadakis, Jen Jen Yeh, Jimmie Ye Chun, Grace E. Kim, Valerie M. Weaver, Matthias HebrokSingle cell transcriptome analysis defines heterogeneity of the murine pancreatic ductal tree. https://doi.org/10.1101/2020.10.12.336784
  2. Honglin Jiang,1 Robert J. Torphy,2 Katja Steiger,3 Henry Hongo,1 Alexa J. Ritchie,1 Mark Kriegsmann,4 David Horst,5 Sarah E. Umetsu,6 Nancy M. Joseph,6 Kimberly McGregor,7 Michael J. Pishvaian,8,9,10 Edik M. Blais,10 Brian Lu,11 Mingyu Li,11 Michael Hollingsworth,12 Connor Stashko,13 Keith Volmar,14 Jen Jen Yeh,15,16,17 Valerie M. Weaver,13 Zhen J. Wang,18 Margaret A. Tempero,1 Wilko Weichert,3 and Eric A. Collisson1. Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix. J Clin Invest. 2020;130(9):4704-4709. https://doi.org/10.1172/JCI136760
  3. Wang MT, Fer N, Galeas J, Collisson EA, Kim SE, Sharib J, McCormick F. Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer. Nat Commun. 2019 Jul 11; 10(1):3055.
    View on PubMed
  4. Shi Y, Gao W, Lytle NK, Huang P, Yuan X, Dann AM, Ridinger-Saison M, DelGiorno KE, Antal CE, Liang G, Atkins AR, Erikson G, Sun H, Meisenhelder J, Terenziani E, Woo G, Fang L, Santisakultarm TP, Manor U, Xu R, Becerra CR, Borazanci E, Von Hoff DD, Grandgenett PM, Hollingsworth MA, Leblanc M, Umetsu SE, Collisson EA, Scadeng M, Lowy AM, Donahue TR, Reya T, Downes M, Evans RM, Wahl GM, Pawson T, Tian R, Hunter T. Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Nature. 2019 05; 569(7754):131-135.
    View on PubMed
  5. Collisson EA, Bailey P, Chang DK, Biankin AV. Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2019 Apr; 16(4):207-220.
    View on PubMed
  6. Walker EJ, Carnevale J, Pedley C, Blanco A, Chan S, Collisson EA, Tempero MA, Ko AH. Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma. Fam Cancer. 2019 Apr; 18(2):241-251.
    View on PubMed
  7. Collisson EA. Bringing Pancreas Cancer into the Lab. Cancer Discov. 2018 Sep; 8(9):1062-1063.
    View on PubMed
  8. Cho RJ, Alexandrov LB, den Breems NY, Atanasova VS, Farshchian M, Purdom E, Nguyen TN, Coarfa C, Rajapakshe K, Prisco M, Sahu J, Tassone P, Greenawalt EJ, Collisson EA, Wu W, Yao H, Su X, Guttmann-Gruber C, Hofbauer JP, Hashmi R, Fuentes I, Benz SC, Golovato J, Ehli EA, Davis CM, Davies GE, Covington KR, Murrell DF, Salas-Alanis JC, Palisson F, Bruckner AL, Robinson W, Has C, Bruckner-Tuderman L, Titeux M, Jonkman MF, Rashidghamat E, Lwin SM, Mellerio JE, McGrath JA, Bauer JW, Hovnanian A, Tsai KY, South AP. APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa. Sci Transl Med. 2018 Aug 22; 10(455).
    View on PubMed
  9. Wang ZJ, Behr S, Consunji MV, Yeh BM, Ohliger MA, Gao K, Ko AH, Cinar P, Tempero MA, Collisson EA. Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI. AJR Am J Roentgenol. 2018 Nov; 211(5):1010-1019.
    View on PubMed
  10. Jha P, Yeh BM, Zagoria R, Collisson E, Wang ZJ. The Role of MR Imaging in Pancreatic Cancer. Magn Reson Imaging Clin N Am. 2018 Aug; 26(3):363-373.
    View on PubMed
  11. North JP, Golovato J, Vaske CJ, Sanborn JZ, Nguyen A, Wu W, Goode B, Stevers M, McMullen K, Perez White BE, Collisson EA, Bloomer M, Solomon DA, Benz SC, Cho RJ. Cell of origin and mutation pattern define three clinically distinct classes of sebaceous carcinoma. Nat Commun. 2018 05 14; 9(1):1894.
    View on PubMed
  12. Lim HC, Montesion M, Botton T, Collisson EA, Umetsu SE, Behr SC, Gordan JD, Stephens PJ, Kelley RK. Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1-Mutant Cholangiocarcinoma Harboring a Novel YWHAZ-BRAF Fusion. Oncologist. 2018 Sep; 23(9):998-1003.
    View on PubMed
  13. Torphy RJ, Wang Z, True-Yasaki A, Volmar KE, Rashid N, Yeh B, Anderson JM, Johansen JS, Hollingsworth MA, Yeh JJ, Collisson EA. Stromal Content Is Correlated With Tissue Site, Contrast Retention, and Survival in Pancreatic Adenocarcinoma. JCO Precis Oncol. 2018; 2018.
    View on PubMed
  14. Aguirre AJ, Collisson EA. Advances in the Genetics and Biology of Pancreatic Cancer. Cancer J. 2017 Nov/Dec; 23(6):315-320.
    View on PubMed
  15. Chen I, Raymond VM, Geis JA, Collisson EA, Jensen BV, Hermann KL, Erlander MG, Tempero M, Johansen JS. Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma. Oncotarget. 2017 Nov 17; 8(58):97769-97786.
    View on PubMed
  16. Korkola JE, Collisson EA, Heiser LM, Oates C, Bayani N, Itani S, Esch A, Thompson W, Griffith OL, Wang NJ, Kuo WL, Cooper B, Billig J, Ziyad S, Hung JL, Jakkula L, Feiler H, Lu Y, Mills GB, Spellman PT, Tomlin C, Mukherjee S, Gray JW. Correction: Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer. PLoS One. 2017; 12(10):e0186551.
    View on PubMed
  17. Katz MHG, Ou FS, Herman JM, Ahmad SA, Wolpin B, Marsh R, Behr S, Shi Q, Chuong M, Schwartz LH, Frankel W, Collisson E, Koay EJ, Hubbard JM, Leenstra JL, Meyerhardt J, O'Reilly E. Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. BMC Cancer. 2017 Jul 27; 17(1):505.
    View on PubMed
  18. Lu X, Peled N, Greer J, Wu W, Choi P, Berger AH, Wong S, Jen KY, Seo Y, Hann B, Brooks A, Meyerson M, Collisson EA. MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma. Cancer Res. 2017 08 15; 77(16):4498-4505.
    View on PubMed
  19. Collisson EA, Maitra A. Pancreatic Cancer Genomics 2.0: Profiling Metastases. Cancer Cell. 2017 03 13; 31(3):309-310.
    View on PubMed
  20. Collisson EA, Olive KP. Pancreatic Cancer: Progress and Challenges in a Rapidly Moving Field. Cancer Res. 2017 03 01; 77(5):1060-1062.
    View on PubMed
  21. Sherman MH, Yu RT, Tseng TW, Sousa CM, Liu S, Truitt ML, He N, Ding N, Liddle C, Atkins AR, Leblanc M, Collisson EA, Asara JM, Kimmelman AC, Downes M, Evans RM. Stromal cues regulate the pancreatic cancer epigenome and metabolome. Proc Natl Acad Sci U S A. 2017 01 31; 114(5):1129-1134.
    View on PubMed
  22. Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh Rde W, Collisson E, Schwartz L, Frankel W, Martin R, Conway W, Truty M, Kindler H, Lowy AM, Bekaii-Saab T, Philip P, Talamonti M, Cardin D, LoConte N, Shen P, Hoffman JP, Venook AP. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg. 2016 08 17; 151(8):e161137.
    View on PubMed

 

Grants

  1. Visualization Hub for Genomics Data Exploration and Translational Discovery
  2. NIH/NCIR01 - Genomics and Functional Characterization of NF1-mutated Lung Cancer
  3. NIH/NICR01 - Tailoring Therapy to Pancreatic Cancer Subtypes
  4. NIH/NCI Optimizing Treatment Approaches to Lung Cancers Harboring MET Exon 14 mutations
  5. NIH/NCI (Dr. Jura's R01) The structural and functional basis of MET exon 14 activation and acquired drug resistance